Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
TUSC2 is a highly conserved lung cancer candidate gene. Zusätzlich bieten wir Ihnen Tumor Suppressor Candidate 2 Antikörper (59) und Tumor Suppressor Candidate 2 Kits (2) und viele weitere Produktgruppen zu diesem Protein an.
Showing 3 out of 4 products:
TUSC2P can suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and may also serve as a prognostic factor for esophageal squamous cell carcinoma patients.
these findings show that the combination of TUSC2-erlotinib induces additional novel vulnerabilities that can be targeted with Auranofin.
Data show that TUSC2 is a direct target of miR-584, which is transcriptionally regulated by TWIST1.
FOXP1, TP53INP1, TNFAIP3, and TUSC2 were identified as miR-19a targets.
The therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR.
TUSC2P and TUSC2 3'-UTR expression inhibits cell proliferation, survival, migration, invasion and colony formation, and increases tumor cell death. TUSC2P and TUSC2 3'-UTR bind to miRNAs and arrest their functions, leading to increased TUSC2 translation.
The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
RNA sequence elements in FUS1 UTRs that regulate FUS1 protein express were identified.
Absence of tumor suppressor FUS1 protein expression is associated with bone and soft tissue sarcomas.
Data show that the recombinant FUS1 plasmid has been successfully cloned, which allows highly efficient FUS1 expression in E.coli strain Rosetta (DE3)2 plys.
The goal of this study was to analyze possible involvement of TUSC2 in malignant pleural mesothelioma.
Myristoylation is required for Fus1-mediated tumor-suppressing activity and suggest a novel mechanism for the inactivation of tumor suppressors in lung cancer.
These results suggest that miR-378 enhances cell survival, tumor growth, and angiogenesis through repression of the expression of two tumor suppressors, Sufu and Fus-1.
FUS1 gene and Fus1 protein abnormalities could be used to develop new strategies for molecular cancer therapy for a significant subset of lung tumors.
These results suggest that the three miRNAs are negative regulators of Fus1 expression in lung cancers.
Overexpression of candidate tumor suppressor geneFUS1 isolated from the 3p21.3 homozygous deletionregion leads to G1 arrest and growth inhibition oflung cancer cells.
This gene is a highly conserved lung cancer candidate gene. No other information about this gene is currently available.
PDGFA associated protein 2
, PDGFA-associated protein 2
, fus-1 protein
, fusion 1 protein
, tumor suppressor candidate 2
, lung cancer candidiate, FUS